Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDT vs STRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STRO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

STRO Overall Winner 6-Pillar Tally: CDT 1 – 4 STRO (1 Tie) Matrix Metrics: CDT 3 – 6 STRO

As of Nov 20, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas STRO carries 44.1/100 (HOLD) at $8.60 (10.0x Forward P/E, -254.7% operating margin).

  • Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDT vs STRO
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40
STRO NASDAQ Head-to-Head Winner
Sutro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
$8.60
-1.38% 1D
Market Cap $144.8M
TTM Revenue $45M
Forward P/E 10.0x
Beta / 30D Vol 1.46β · 76% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.6%), weak momentum, RSI 35
RSI-14: 34.5 · SMA20: $9.36 · SMA50: $12.22

6-Pillar Scorecard Institutional Category Breakdown (CDT 1 – 4 STRO)

Columns: Metric · CDT · STRO
1. Valuation Multiples STRO
Forward P/E N/M 10.0x
Trailing P/E N/M 10.0x
PEG Ratio N/M N/M
EV / Revenue N/M 3.2x
2. Growth & Scale STRO
Revenue Growth (YoY) +0.0% -6.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $45M
Market Cap $507,528 $144.8M
3. Profitability & Quality CDT
Gross Margin N/A N/A
Operating Margin 0.0% -254.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -69.7% -1810.0%
4. Balance Sheet & Cash Flow STRO
Cash Generation (TTM) N/A -$109M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $435,000 Net Debt (0.01x D/E) -1810.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STRO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) 122.4% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDT (3) vs STRO (6)
Institutional Metric CDT STRO Criterion Row Edge
Market Capitalization
Scale
$507,528 $144.8M Larger Scale STRO
Trailing P/E Ratio
Valuation
N/M 10.0x Lower Multiple STRO
Forward P/E Ratio
Valuation
N/M 10.0x Lower Multiple STRO
Revenue Growth (YoY)
Growth
+0.0% -6.1% Higher Growth CDT
Operating Margin (TTM)
Profitability
0.0% -254.7% Higher Margin CDT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-69.7% -1810.0% Higher ROE CDT
52-Week Range Position
Momentum
2% ($0–$11) 18% ($1–$44) Stronger Trend STRO
Beta / 30D Volatility
Risk Regime
-17.75β · 10175% Vol 1.46β · 76% Vol Lower Realized Risk STRO
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 44.1 / 100 (HOLD) Higher Composite STRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $45M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($435,000 Net Debt (0.01x D/E)) -$109M EBITDA (-1810.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +93.21 pp
CDT: +76.79% · STRO: -16.42%
3M Horizon STRO +32.73 pp
CDT: -90.76% · STRO: -58.03%
6M Horizon STRO +11.73 pp
CDT: -78.1% · STRO: -66.37%
1Y Horizon STRO +931.83 pp
CDT: -86.78% · STRO: +845.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs STRO. Trailing 12-month operating profitability (CDT 0.0% vs STRO -254.7%) and valuation multiples (CDT N/M vs STRO 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.

CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M
STRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$45M
Gross MarginN/A
Op. Margin-254.7%
ROE / Fwd P/E-1810.0% · 10.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 122.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $144.8M market capitalization and -254.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDT vs STRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Sutro Biopharma, Inc. (STRO) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas STRO carries 44.1/100 (HOLD) at $8.60 (10.0x Forward P/E, -254.7% operating margin). Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STRO leads the Growth & Scale pillar: CDT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with STRO at -6.1% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (N/A gross margin, -254.7% operating margin). On trailing 12-month operating scale, CDT generates N/A in USD-normalized revenue versus $45M for STRO. In operating R&D and SG&A reinvestment, CDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STRO.

STRO screens cheaper on headline valuation multiples. CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas STRO trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDT (-69.7% ROE) versus STRO (-1810.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk). By comparison, STRO carries 122.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.46β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.